N@N

Debjit Chattopadhyay Reiterated (BMRN) at Strong Buy and Held Target at $110 on, Sep 13th, 2023

^{Published on 2024-10-28 06:23:03 - WOPRAI, Debjit Chattopadhyay}
 

Debjit Chattopadhyay of Guggenheim, Reiterated "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy and Held Target at $110 on, Sep 13th, 2023.

Debjit has made no other calls on BMRN in the last 4 months.

There are 11 other peers that have a rating on BMRN. Out of the 11 peers that are also analyzing BMRN, 4 agree with Debjit's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Andreas Argyrides of "Wedbush" Maintained at Hold with Decreased Target to $70 on, Tuesday, August 1st, 2023
• George Farmer of "Scotiabank" Initiated at Hold and Held Target at $95 on, Thursday, July 27th, 2023
• Whitney Ijem of "Canaccord Genuity" Maintained at Hold with Decreased Target to $104 on, Monday, July 3rd, 2023
• David Lebowitz of "Citigroup" Maintained at Hold with Decreased Target to $96 on, Friday, June 30th, 2023

These are the ratings of the 7 analyists that currently disagree with Debjit

---

• Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $125 on, Tuesday, August 1st, 2023
• Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $108 on, Tuesday, August 1st, 2023
• Geoff Meacham of "B of A Securities" Maintained at Strong Buy with Decreased Target to $185 on, Friday, July 21st, 2023
• Kostas Biliouris of "BMO Capital" Upgraded from Hold to Buy and Held Target at $102 on, Wednesday, July 5th, 2023
• Joel Beatty of "Baird" Reiterated at Buy and Held Target at $127 on, Friday, June 30th, 2023
• Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $140 on, Friday, June 30th, 2023
• Tiago Fauth of "Credit Suisse" Initiated at Buy and Held Target at $120 on, Wednesday, June 14th, 2023

Contributing Sources

---